Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Explore this paper's citation graph
Summary
IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.
- Type
- article
- Published
- 2009-04-10
- Cited by
- 1,118
- References
- 12
- OpenAlex
- https://openalex.org/W1964150693
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:12649638
Keywords
IDH1, Isocitrate dehydrogenase, Carcinogenesis, Mutant, Biology
References
- Multiple NADPH-producing pathways control glutathione (GSH) content in retina.
- Structures of Human Cytosolic NADP-dependent Isocitrate Dehydrogenase Reveal a Novel Self-regulatory Mechanism of Activity*
- Mechanism of the inhibitory effect of glyoxylate plus oxaloacetate and oxalomalate on the NADP-specific isocitrate dehydrogenase.
- Cellular concentrations of enzymes and their substrates.
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- Evaluation of HIF-1 inhibitors as anticancer agents.
- Identification by Mutagenesis of Arginines in the Substrate Binding Site of the Porcine NADP-dependent Isocitrate Dehydrogenase*
- Analysis of the IDH1 codon 132 mutation in brain tumors
- IDH1 and IDH2 Mutations in Gliomas
- Cell-Permeating α-Ketoglutarate Derivatives Alleviate Pseudohypoxia in Succinate Dehydrogenase-Deficient Cells
- Malignant astrocytic glioma: genetics, biology, and paths to treatment.
- IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high‐grade gliomas but not in other solid tumors
Cited by
- Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism.
- Anaplastische Gliome
- Oncology's energetic pipeline
- IDH1 and IDH2 mutations in myeloid neoplasms – Novel paradigms and clinical implications
- Leukemia stem cells and microenvironment: biology and therapeutic targeting.
- Impaired TCA cycle flux in mitochondria in skeletal muscle from type 2 diabetic subjects: Marker or maker of the diabetic phenotype?
- Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies
- Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.
- Chronic hypoxia leads to a glycolytic phenotype and suppressed HIF-2 signaling in PC12 cells.
- Oncometabolites‐driven tumorigenesis: From genetics to targeted therapy
- New Developments in the Pathogenesis and Therapeutic Targeting of the IDH1 Mutation in Glioma
- Interrogating IDH Mutation in Brain Tumor: Magnetic Resonance and Hyperpolarization
- Glioma biology and molecular markers.
- IDH mutation-specific radiomic signature in lower-grade gliomas
- Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications
- Genetic Dissection of the Biological and Molecular Role of IDH1 Mutations in Glioma
- Prevalence of SPOP and IDH Gene Mutations in Prostate Cancer in a Jordanian Population
- Estudo de marcadores de diagnóstico e prognóstico em gliomas
- Driving Brain Tumorigenesis: Generation and Biological Characterization of a Mutant IDH1 Mouse Model
- The Effect of Isocitrate Dehydrogenase on the Epigenetics of Human Mitochondrial DNA
Related papers
- Isocitrate dehydrogenase 1 mutations and human gliomas
- Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
- Inhibition of mutant IDH1 in acute myeloid leukaemia.
- New insights into glioma classification based on isocitrate dehydrogenase 1 and 2 gene status
- Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?
- Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target
- Metabolism, gliomas, and IDH1.
- Isocitrate dehydrogenase 1and 2 gene mutation status– a critical parameter in the diagnosis and prognosis of adult gliomas
- Isocitrate dehydrogenase mutations in gliomas.
- Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.